DarioHealth Corp. (DRIO) stock
DRIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3099% below fair value
$1.15−0.11 (-8.73%)
Close on Nov 16, 2026Market cap $11.27MP/E 0.3Yield –
DarioHealth EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
DarioHealth's EPS for the twelve months ending Jun 30, 2026 was $3.92. For fiscal 2025 it was $10.12, down 17.5% from the year before. Over ten years it grew -18.3% a year on average. The highest annual figure on record is $1368.00 in fiscal 2013.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.12 | -17.5% |
| FY2024 | Dec 31, 2024 | $12.27 | +535.8% |
| FY2023 | Dec 31, 2023 | $1.93 | -24.0% |
| FY2022 | Dec 31, 2022 | $2.54 | -37.6% |
| FY2021 | Dec 31, 2021 | $4.07 | +1.5% |
| FY2020 | Dec 31, 2020 | $4.01 | -49.9% |
| FY2019 | Dec 31, 2019 | $8.00 | -48.8% |
| FY2018 | Dec 31, 2018 | $15.63 | -52.3% |
| FY2017 | Dec 31, 2017 | $32.80 | -21.5% |
| FY2016 | Dec 31, 2016 | $41.80 | -45.6% |
| FY2015 | Dec 31, 2015 | $76.80 | -88.5% |
| FY2014 | Dec 31, 2014 | $666.00 | -51.3% |
| FY2013 | Dec 31, 2013 | $1368.00 | +65.2% |
| FY2012 | Dec 31, 2012 | $828.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.85 | -76.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.25 | -56.4% |
| Q4 FY2025 | Dec 31, 2025 | -$1.14 | -123.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.96 | +3600.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.54 | +1670.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.87 | +485.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.91 | +746.6% |
| Q2 FY2024 | Jun 30, 2024 | $0.08 | -82.2% |
| Q1 FY2024 | Mar 31, 2024 | $0.20 | -68.8% |
| Q3 FY2023 | Sep 30, 2023 | $0.49 | -33.8% |
| Q2 FY2023 | Jun 30, 2023 | $0.58 | -21.6% |
| Q1 FY2023 | Mar 31, 2023 | $0.45 | -61.9% |
| Q3 FY2022 | Sep 30, 2022 | $0.64 | -35.4% |
| Q2 FY2022 | Jun 30, 2022 | $0.74 | -19.6% |
| Q1 FY2022 | Mar 31, 2022 | $0.74 | – |
| Q3 FY2021 | Sep 30, 2021 | $1.18 | – |
| Q2 FY2021 | Jun 30, 2021 | $0.99 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.92 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.71 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.68 | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.57 | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.11 | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.50 | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.92 | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.40 | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.40 | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.60 | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.00 | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?